Ouzama Henry, Vice President, Clinical Development

Dr. Ouzama Henry joined Dynavax in 2022 and currently serves as Vice President, Clinical Development. Dr. Henry has more than 14 years of vaccine and infectious disease experience. Before joining Dynavax, she served in multiple roles at GSK vaccines, most recently as Vice President and Head, Clinical Research and Development at GSK Vaccines, where she oversaw the development of global clinical epi plans for a range of vaccine candidates and licensed vaccines. Previously, Dr. Henry conducted infectious disease and vaccine clinical research with Merck & Co., Inc. Dr. Henry was an Instructor of Medicine at Harvard Medical School.

Dr. Henry holds a Master of Science in Epidemiology from Columbia University, a Medical Doctorate from Harvard Medical School, and a Bachelor of Arts in Biology from Harvard College. She has published 27 scientific articles in a variety of journals.